CARG-201
/ CaroGen, Albany Medical College, Yale School of Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 22, 2021
CaroGen Partners with BioCentriq for Clinical Production of its Novel Immunotherapy CARG-201
(PRWeb)
- "CaroGen Corporation has selected BioCentriq™ as their partner for clinical manufacturing to support Phase 1 clinical trials of its lead immunotherapy candidate, CARG-201 which has been designed to generate multiple hepatitis B virus (HBV) antigens and to stimulate broad immune responses."
Licensing / partnership • Hepatitis B • Infectious Disease
1 to 1
Of
1
Go to page
1